Rathbones Group PLC Increases Stock Position in Guardant Health, Inc. (NASDAQ:GH)

Rathbones Group PLC lifted its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 4.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 108,395 shares of the company’s stock after purchasing an additional 4,667 shares during the period. Rathbones Group PLC owned about 0.09% of Guardant Health worth $3,130,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Norges Bank acquired a new position in Guardant Health in the 4th quarter valued at about $25,520,000. Duality Advisers LP purchased a new position in shares of Guardant Health during the first quarter valued at approximately $1,154,000. Vanguard Group Inc. lifted its stake in shares of Guardant Health by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 11,130,654 shares of the company’s stock valued at $301,084,000 after buying an additional 180,424 shares during the period. Wellington Management Group LLP boosted its position in Guardant Health by 24.1% during the fourth quarter. Wellington Management Group LLP now owns 834,084 shares of the company’s stock worth $22,562,000 after acquiring an additional 161,986 shares during the last quarter. Finally, Swiss National Bank grew its stake in Guardant Health by 3.3% in the 1st quarter. Swiss National Bank now owns 227,700 shares of the company’s stock worth $4,697,000 after acquiring an additional 7,300 shares during the period. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

GH has been the topic of several analyst reports. Citigroup raised their price objective on Guardant Health from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Guggenheim upgraded Guardant Health from a “neutral” rating to a “buy” rating and set a $36.00 price target for the company in a report on Friday, June 28th. JPMorgan Chase & Co. increased their price objective on shares of Guardant Health from $45.00 to $48.00 and gave the stock an “overweight” rating in a report on Thursday, August 8th. The Goldman Sachs Group raised their target price on shares of Guardant Health from $28.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, July 17th. Finally, TD Cowen increased their price target on shares of Guardant Health from $41.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $39.31.

Guardant Health Stock Up 4.7 %

Shares of NASDAQ:GH opened at $26.79 on Monday. The company has a market capitalization of $3.28 billion, a price-to-earnings ratio of -6.83 and a beta of 1.11. The company has a 50 day moving average of $29.20 and a two-hundred day moving average of $24.88. Guardant Health, Inc. has a 52-week low of $15.81 and a 52-week high of $37.04. The company has a quick ratio of 6.07, a current ratio of 6.40 and a debt-to-equity ratio of 16.70.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.10). Guardant Health had a negative net margin of 76.23% and a negative return on equity of 418.21%. The firm had revenue of $177.24 million for the quarter, compared to analyst estimates of $162.59 million. During the same period in the previous year, the business posted ($0.67) earnings per share. Guardant Health’s revenue for the quarter was up 29.2% on a year-over-year basis. As a group, analysts forecast that Guardant Health, Inc. will post -3.3 earnings per share for the current fiscal year.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.